文献速递肾移植

移植后淋巴增殖性疾病可能增加肾移植受者死亡风险但不影响移植物丢失

Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.
PubMed 文献 · Kidney Int · 2018-08-30

该研究基于ANZDATA注册数据,将367例PTLD患者与1468例对照按1:4匹配,随访平均16年,发现PTLD患者10年生存率低于对照组,死亡风险主要在移植后前2年增加,但移植物丢失风险无显著增加。脑淋巴瘤、骨髓疾病及2000年前诊断是死亡风险因素,2000年后总体生存改善。

要点

  • PTLD与肾移植受者死亡风险增加相关,尤其诊断后前2年。
  • PTLD未显著增加移植物丢失风险。
  • 脑淋巴瘤、骨髓疾病及2000年前诊断是死亡风险因素。

核心结论

  • PTLD是肾移植受者死亡的风险因素,尤其在诊断后前两年,但不增加移植物丢失风险。

研究设计与样本

  • 基于ANZDATA注册的匹配队列研究,367例PTLD患者按1:4匹配1468例对照,随访平均16年。

主要发现

  • PTLD患者10年生存率为41%(95%CI 36-47%),低于对照组的65%(95%CI 63-68%)。
  • 移植后前2年死亡风险显著增加(HR 8.5,95%CI 6.7-11),之后无显著增加(HR 1.0,95%CI 0.76-1.3)。
  • 脑淋巴瘤(HR 2.0,95%CI 1.3-3.1)、骨髓疾病(HR 2.0,95%CI 1.2-3.3)及2000年前诊断(HR 2.2,95%CI 1.4-3.5)是死亡风险因素。
  • PTLD未显著增加移植物丢失风险(HR 1.08,95%CI 0.69-1.70)。

临床怎么用

  • 对PTLD肾移植受者,应重点关注诊断后前两年的死亡风险,加强监测和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Better prognostication of graft and patient outcomes among kidney transplant recipients with post-transplant lymphoproliferative disease (PTLD) in the rituximab era is needed to inform treatment decisions. Therefore, we sought to estimate the excess risks of death and graft loss in kidney transplant recipients with PTLD, and to determine risk factors for death. Using the ANZDATA registry, the risks of mortality and graft loss among recipients with and without PTLD were estimated using survival analysis. A group of 367 patients with PTLD (69% male, 85% white, mean age 43 years) were matched 1 to 4 to 1468 controls (69% male, 88% white, mean age 43 years), and followed for a mean of 16 years. Recipients with PTLD experienced poorer 10-year patient survival (41%, 95% confidence intervals 36-47%) than controls (65%, 63-68%). Excess mortality occurred in the first 2 years post-transplant (hazard ratio 8.5, 6.7-11), but not thereafter (1.0, 0.76-1.3). Cerebral lymphoma (2.0, 1.3-3.1), bone marrow disease (2.0, 1.2-3.3) and year of diagnosis prior to 2000 (2.2, 1.4-3.5; after 2000 reference) were risk factors of death. PTLD did not confer an excess risk of graft loss (1.08, 0.69-1.70). Thus, PTLD is a risk factor for death, particularly in the first two years after diagnosis. Cerebral or bone marrow diseases were associated with increased mortality risk, but overall survival in the rituximab era (post 2000) has improved.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Francis A, Johnson DW, Craig J, et al. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients. Kidney Int. 2018. PMID: 30173897. doi:10.1016/j.kint.2018.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。